Second dose of IV immunoglobulin 'might be harmful' in Guillain-Barre syndrome

The first randomised controlled trial testing efficacy found no benefit and an increased risk of thromboembolic events

Giving patients with severe Guillain-Barre syndrome a repeat dose of intravenous immunoglobulin is unlikely to provide a clinical benefit and may do harm, Dutch researchers say.

Their randomised controlled trial in 59 hospitals in the Netherlands between 2010 and 2018 is the first to examine the efficacy and safety of giving a second dose of intravenous immunoglobulin (IVIg).

About one quarter of nonresponders receive a second dose, a practice which appears to be based only on a small uncontrolled case series and